Novo Nordisk, which lobbied to win Medicaid reimbursement for its obesity drug Wegovy, is fighting to keep that coverage as ...

The Ozempic maker’s controlling shareholder intends to replace seven directors, including the Denmark-based company’s ...

After clearing Novo Nordisk’s semaglutide treatments Ozempic and Wegovy to reduce the risk of major adverse cardiovascular ...

The chair and six independent directors of Novo Nordisk are stepping down after a dispute with the Danish drugmaker’s ...

A closely watched pill from Novo Nordisk just scored an approval for slashing cardiovascular risks, while Mark Cuban gives ...

Novo Nordisk's chairman Helge Lund and several other independent board members have indicated they will step down next month, ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY) shares fell more than 4% each in premarket trading on Friday following comments from President Trump a day earlier regarding potential price reductions ...

The president said the cost of the drug should be much lower for Americans once negotiations with Novo Nordisk had concluded.

Novo Nordisk A/S Chairman Helge Lund is stepping down after a boardroom dispute over governance and will be replaced by Lars Rebien Sorensen, a previous leader of the company who now heads its biggest ...

The downturn at Novo Nordisk A/S could deal a further blow to Danish consumer confidence, with the drugmaker’s slumping ...

Novo Nordisk faces a governance shakeup as seven board members quit amid a power clash with the controlling Foundation.